Pancreatic Cancer Clinical Trials in Phoenix

Showing 41-60 of 121 trials

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

NCT02723331

The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).

Pancreatic CancerPancreatic AdenocarcinomaPancreas Ductal Adenocarcinoma

Academic Thoracic Oncology Medical Investigators Consortium48 participantsStarted Dec 2016

Scottsdale, Arizona, United States • Tucson, Arizona, United States • Aurora, Colorado, United States +1 more locations

TERMINATEDPhase 1/211 miles

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

NCT04203641

This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.

Pancreas Cancer

Helix BioPharma Corporation28 participantsStarted Dec 2019

Scottsdale, Arizona, United States • Morristown, New Jersey, United States • Milwaukee, Wisconsin, United States

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Milademetan in Advanced/Metastatic Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Other Conditions in Phoenix